Background
The Carpentier-Edwards Perimount valves have a proven track record in
aortic valve replacement: good durability, hemodynamic performance,
rates of survival, and low rates of valve-related complications and PPM.
The St. Jude Medical Trifecta is a newer valve that has shown comparable
early and midterm outcomes. Studies show reoperation rates of Trifecta
are comparable to Perimount valves, with a few recent studies bringing
into focus early SVD, and increased midterm SVD in younger patients.
Given that midterm data for Trifecta is still sparse, we wanted to
confirm the early low reoperation rates of Trifecta persist over time
compared to Perimount.